| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= mean sitting DBP 100‐115 mm Hg at both week 3 and week 4 run‐in visits, with a difference of 10 mm Hg or less between two visit means; 8‐week double‐blind treatment |
| Participants |
Olmesartan 20 mg: n=188(116 males, 72 females); mean age=51.7 years; baseline sitting SBP=154.9 mm Hg, DBP=104.0 mm Hg;
Placebo: n=66(44 males,22 females); mean age=52.0 years; baseline sitting SBP=154.2 mm Hg, DBP=103.3 mm Hg |
| Interventions |
Olmesartan 20 mg once daily;
Placebo;
taken at 8 AM (± 1.5 h) |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP;
WDAE |
| Notes |
BP change reported, SD of change not reported, endpoint BP and SD not reported, baseline SD not reported; imputed overall trial mean SBP/DBP SD of change; BP data from Table 3, p. 429; BP measurement device not reported; Jadad score=3; funding source= Sankyo Pharma |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
